ORAMED PHARMACEUTICALS INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2023-09-30 was -$2.00K, a 100.05% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $0.00.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $2.43M, a 18.15% decline year-over-year.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2023 was $2.43M, a 78.89% decline from fiscal 2022.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2022 was $11.50M.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2021 was $79.98M, a 236.44% increase from fiscal 2020.
- ORAMED PHARMACEUTICALS INC. stock issued during period, value, new issues for fiscal 2020 was $23.77M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.43M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $6.58M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $10.96M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.43M 10-Q · filed 2024-05-09 | $10.96M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $11.50M 10-K · filed 2024-03-06 |
| 2022-09-30 | $4.38M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | -$1.00K 10-Q · filed 2023-08-10 | |
| 2022-03-31 | $2.97M 10-Q · filed 2023-05-11 | |
| 2021-11-30 | $59.94M 10-Q · filed 2022-01-11 | |
| 2021-09-30 | $27.60M 10-Q · filed 2022-11-10 | |
| 2021-08-31 | $38.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $79.98M 10-K · filed 2023-03-06 |
| 2021-06-30 | $24.83M 10-Q · filed 2022-08-10 | |
| 2021-05-31 | $18.87M 10-Q · filed 2021-07-14 | |
| 2021-03-31 | $22.31M 10-Q · filed 2022-05-12 | |
| 2021-02-28 | $21.67M 10-Q · filed 2021-04-13 | $43.72M derived: sum of 4 quarters · filed 2022-01-11 |
| 2020-11-30 | $586.00K 10-Q · filed 2022-01-11 | $24.36M derived: sum of 4 quarters · filed 2022-01-11 |
| 2020-08-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $23.77M 10-K · filed 2021-11-24 |
| 2020-05-31 | $19.98M 10-Q · filed 2021-07-14 | |
| 2020-02-29 | $2.32M 10-Q · filed 2021-04-13 | |
| 2018-08-31 | $16.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-28 | $21.66M 10-K · filed 2018-11-28 |
| 2018-05-31 | $283.00K 10-Q · filed 2019-07-10 | |
| 2018-02-28 | $651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-04-10 | |
| 2017-11-30 | $4.23M 10-Q · filed 2019-01-14 | |
| 2017-08-31 | $25.00K 10-K · filed 2019-11-27 | |
| 2016-08-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-28 | $10.59M 10-K · filed 2018-11-28 |
| 2016-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-07-06 | |
| 2015-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-07-01 | |
| 2015-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-04-03 | |
| 2014-11-30 | $4.83M 10-Q · filed 2015-01-08 | |
| 2014-08-31 | $14.89M 10-K · filed 2015-11-25 | |
| 2013-08-31 | -$592.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-14 | $1.42M 10-K · filed 2014-11-14 |
| 2012-11-30 | $1.43M 10-Q · filed 2012-12-26 | |
| 2012-08-31 | $3.00M 10-K · filed 2014-11-14 | |
| 2011-08-31 | $3.69M 10-Q · filed 2014-04-10 | |
| 2008-08-31 | $5.78M 10-Q · filed 2014-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |